Trial Profile
An observational, multicentre, retrospective study to evaluate the outcomes of second-line ipilimumab in a real-world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2017 New trial record
- 11 Apr 2017 Results published in the Journal of Chemotherapy